Trial Profile

A Randomized Phase 2 Trial to Evaluate Three Daratumumab Dose Schedules in Smoldering Multiple Myeloma

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 04 Mar 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Daratumumab (Primary) ; Daratumumab (Primary)
Indications Smoldering multiple myeloma
Focus Therapeutic Use
Acronyms CENTAURUS
Sponsors Janssen Research & Development; Janssen-Cilag

Most Recent Events

16 Aug 2024 Status changed from active, no longer recruiting to completed.
21 Jun 2024 This trial has been completed in France (Global end date: 3 June 2024).
12 Dec 2023 Final analysis presented at the 65th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com